NCT07448896Completed
Gastric Mucosal Mast Cells, Macrophages and Microvessels in Obesity
Gastric Mucosal Mast Cells, Macrophages and Microvessels in Patients With Obesity Undergoing Sleeve Gastrectomy: A Comparative Cross-Sectional Immunohistochemical Study
Source: ClinicalTrials.gov · Last updated 9 Oct 2026
Brief summary (registry, in English)
This comparative cross-sectional study compared tryptase-positive mast cells, CD68-positive macrophages, and CD31-positive microvessels in the gastric mucosa of 31 patients with obesity undergoing sleeve gastrectomy and 33 participants without obesity undergoing diagnostic endoscopy. Active Helicobacter pylori infection, recent smoking, and overt mucosal disease were excluded.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 64 (actual)
- First submitted
- 20 Feb 2026
- Start date
- 1 Jan 2025
- Primary completion date
- 13 May 2026
- Lead sponsor
- General Committee of Teaching Hospitals and Institutes, Egypt
- Diseases
- Obesity
- NCT number
- NCT07448896
What you commit to
- Study type: Observational
- Participants enrolled: 64
- From 1 Jan 2025 to the primary completion date, 13 May 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Current cigarette smoking, or smoking cessation within 6 months before enrollment.
- Prior gastric surgery.
- Active malignancy, or a major systemic infection within 3 months before sampling.
- Long-term non-steroidal anti-inflammatory drug use, proton pump inhibitor use for more than 6 months, or immunosuppressive or corticosteroid therapy within 3 months before sampling.
Other illness
- Active erosive gastritis, peptic ulcer disease, or suspected or confirmed gastric malignancy at endoscopy.
- Secondary causes of obesity, such as Cushing's syndrome or hypothyroidism.
- Systemic autoimmune disease or inflammatory bowel disease.
Other
- Positive rapid urease test.
- For controls: BMI of 30 kg/m² or higher.
Who the study is looking for
- Cases: patients aged 17 years or older with obesity scheduled for elective sleeve gastrectomy according to the 2022 ASMBS/IFSO indications for metabolic and bariatric surgery.
- Controls: participants aged 17 years or older with BMI below 30 kg/m² undergoing diagnostic upper gastrointestinal endoscopy for benign indications, such as mild dyspepsia, with no endoscopic evidence of active gastric mucosal disease.
- Negative rapid urease test for Helicobacter pylori on antral biopsy.
- Written informed consent.
Age in the registry: 17 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| The surgical department of Medical Research Institute Hospital, Alexandria University Coordinator of this site? Confirm its status | Alexandria | Egypt | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.